Men with Breast Cancer Have Worse Mortality, Highlight Need for Better Awareness

Article

A new study found men with breast cancer have higher mortality compared with women, possibly due to lack of awareness.

Men with breast cancer had a higher mortality rate when compared with women with breast cancer, reported a cohort study recently published in JAMA Oncology. This overall finding aligns with what previous studies have found and highlight the need for better awareness about male breast cancer.

“Most people with breast cancer are found to have breast cancer because they have a lump in their breast, and you would think that in men it would be easier to find a lump in the breast,” said Joanne Mortimer, MD, director of City of Hope’s Women’s Cancer Programs, who was not involved with the study, during an interview with CancerNetwork. “Unfortunately, people's suspicion about what's going on in the breast of a man is not the same as a woman.”

The study was conducted using the National Cancer Database, and 1,816,733 patients with a breast cancer diagnosis between January 1, 2004, and December 31, 2014 were identified. The totals were 1,800,708 women- and 16,025 men.

Men with breast cancer had a significantly worse overall survival (OS) rate (45.8% vs 60.4%; P < .001), 3-year OS rate (86.4% vs 91.7%; P < .001), and 5-year OS rate (77.6% vs 86.4%; P < .001) compared with women with breast cancer, according to the data.

Even when men were diagnosed at the same disease stage as women, their survival outcomes were still inferior. For the 5-year OS rate, men had worse survival than women at stage I (87.8% vs 92.5%; P < .001), stage II (78.9% vs 85.9%; P < .001), stage III (63.3% vs 70.1%; P < .001), and stage IV disease (21.4% vs 25.1%; P = .007).

Several factors were associated with a higher mortality rate among men, including age, clinical characteristics, treatment received, access to care, and race/ethnicity.

However, when all these factors were controlled for, men still have worse survival. The study authors pointed out that this suggests that other factors, particularly additional biological attributes, treatment compliance, and lifestyle factors, should be identified to help in eliminating this disparity.

Clinical and treatment characteristics were the primary factors linked to worse survival, they added.

“Clinical characteristics and undertreatments were associated with 63.3% of the excess mortality among male patients,” the authors wrote.

The cohort study also revealed that a higher proportion of men were diagnosed with more advanced disease, yet less likely to receive standard treatment. For example, men with hormone receptor-positive breast cancer were less likely to receive adjuvant endocrine therapy compared with women.

“These endocrine therapies are very effective at increasing the cure rate of breast cancer,” Mortimer. “It's unfortunate that these men did not get endocrine therapy as part of their treatment.”

In fact, Don Hoffman, a male breast cancer patient who Mortimer helped care for, exemplifies the importance of early detection and proper treatment for men.

“Man or woman, early detection is a lifesaver,” said Hoffman. He noticed the nipple and areola on his left breast were flatter than usual and had his breast checked by his primary care physician. A mammogram showed a small mass, which was treated. “My early detection probably made me a better candidate to live longer.”

To Hoffman, one reason why men may be diagnosed later on, when outcomes are worse, is a man’s attitude toward seeking medical care. “A man's attitude is, ‘Oh, I can tough this out, this is not a big deal,’” Hoffman said. “I think that mindset works against men.”

Disclosures:

Wang F, Shu X, Meszoely I. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol. Published online September 19, 2019.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.